Drugs · acquisition-cost intelligence
XELSTRYM
DEXTROAMPHETAMINE· ingredient dextroamphetamine· DEXTROAMPHETAMINE 13.5 mg/1; DEXTROAMPHETAMINE 18 mg/1; DEXTROAMPHETAMINE 4.5 mg/1; DEXTROAMPHETAMINE 9 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$16.26
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 5 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other dextroamphetamine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Adderall | $0.25990 | −$16.00 |
| Zenzedi | $0.42657 | −$15.84 |
| Adderall XR | $0.54992 | −$15.71 |
| PROCENTRA | $1.11 | −$15.15 |
| DEXEDRINE SPANSULE | $1.34 | −$14.93 |
| Mixed Salts of a Single-Entity Amphetamine Product | $8.51 | −$7.75 |
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.